m 16209 has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ida, K; Kato, K; Miwa, I; Mizota, M; Murakami, N; Nakayama, K; Ohta, M; Okuda, J | 1 |
| Kato, K; Miwa, I; Mizota, M; Murakami, N; Nakayama, K; Notsu, T; Ohta, M; Okuda, J | 1 |
2 other study(ies) available for m 16209 and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
Topics: Aldehyde Reductase; Animals; Benzofurans; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydantoins; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Rats; Rats, Wistar; Streptozocin | 1995 |
Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats.
Topics: Aldehyde Reductase; Animals; Benzofurans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydantoins; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Pancreas; Perfusion; Potassium Channels; Rats; Rats, Wistar; Streptozocin | 1995 |